增强疗法在患有α-1抗素缺乏和慢性阻塞性肺病的个体中调节系统性炎症
J Lascano1, L Riley2, N Khodayari1
1University of Florida, Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, Gainesville, Florida, United States.
Chronic obstructive pulmonary diseases (Miami, Fla.)
|June 26, 2023
概括
慢性肺炎患者的α-1抗素 (AAT) 缺乏症显示出较高的C-反应蛋白 (CRP) 水平,表明系统性炎症. 对AAT缺乏症的增强疗法可以降低CRP,这表明对控制炎症有好处.
科学领域:
- 肺部医学 肺部医学
- 遗传学 遗传学 是一个
- 免疫学 免疫学 免疫学
背景情况:
- 阿尔法-1抗素 (AAT) 缺乏症是一种与慢性阻塞性肺病 (COPD) 相关的遗传疾病.
- AAT是一种具有抗炎性能的蛋白酶抑制剂,其缺乏可以导致系统性炎症增加.
- 在患有COPD的AAT缺乏个体中研究C反应性蛋白 (CRP) 水平可以阐明系统性炎症的程度.
研究的目的:
- 在阿尔法-1抗素 (AAT) 缺乏和COPD的个体中评估血C反应蛋白 (CRP) 水平.
- 为了确定AAT增强疗法是否影响CRP水平和全身炎症.
- 探索AAT缺乏COPD患者肺功能和CRP水平之间的相关性.
主要方法:
- 招募了AAT缺陷个体和匹配的对照队列.
- 使用基于Taqman的测定来确定AAT基因型.
- 通过脑膜测量测量血AAT和CRP水平,并使用未配对的t测试和皮尔森相关性进行分析.
主要成果:
- 与对照组 (n=40) 相比,AAT缺乏的参与者 (n=742) 的AAT和CRP水平显著不同.
- 接受增强疗法的AAT缺乏个体显示CRP水平较低 (0.32±0.53mg/dL) 比未接受增强疗法的个体 (0.69±1.97mg/dL).
- 在没有增强疗法的AAT缺乏个体中,在1秒内强制呼气体积 (FEV1) 和CRP之间观察到负相关性.
结论:
- 患有COPD的AAT缺乏个体表现出循环CRP的升高,表明系统性炎症升高.
- 在这些患者中,AAT增强疗法与血CRP水平降低有关.
- 这些发现表明,增强疗法可能有助于减轻AAT缺乏COPD的全身炎症.
相关概念视频
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.9K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.9K
01:26COPD: Management Using Bronchodilators and Corticosteroids
255
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
255
01:29Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K
01:19Antiasthma Drugs: Leukotriene Modifiers
371
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
371
01:20Asthma: Pathogenesis and Management
458
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
458
01:22Chronic Obstructive Pulmonary Disease
1.3K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.3K